1. At a Glance – The Generic Giant With Global Drama
Market Cap: ₹66,699 Cr.
Current Price: ₹1,147
Stock P/E: 18.9
ROCE: 14.2%
ROE: 11.1%
Debt to Equity: 0.22
3-Month Return: -5.26%
Welcome to Aurobindo Pharma, India’s second-largest listed pharma company by revenue and the largest generics player in the US. Q3 FY26 (Dec 2025 quarter) delivered ₹8,646 Cr in sales and ₹910 Cr in profit, with operating margins holding at 21%. Not bad. Not dazzling. Just solid like that one topper in class who never makes noise but quietly scores 88%.
But here’s the masala — this is a ₹66,000+ Cr company trading at a P/E of 18.9, while the pharma industry median P/E is 29.8. Is Mr. Market saying, “I don’t trust you fully yet”?
US exposure is 53%. Europe is 30%. 90% international revenue. Multiple US FDA inspections. Form 483 observations. Renewable energy investments. Biosimilars in Canada. Acquisitions in India.
This is not boring pharma. This is corporate Netflix.
So the big question — is this a steady compounding machine or a regulatory stress machine in disguise?
Let’s open the blister pack.
2. Introduction – The Quiet Global Operator
Aurobindo doesn’t scream in headlines like some flashy biotech startup promising miracle molecules.
It does something simpler — it manufactures medicines. Lots of them. Across 150+ countries. From oral tablets to injectables, anti-retrovirals to antibiotics.
87% of revenue comes from formulations. APIs contribute 13%. Which means they’re not just selling ingredients — they’re selling finished products. That’s where margins live.
And here’s the twist — they are one of the few companies operating in both beta-lactam and non-beta-lactam APIs. Translation? They play in both the noisy and the silent chemical playgrounds.
But growth hasn’t been spectacular. Sales CAGR over 5 years: 6.55%. Profit growth 5-year CAGR: 3.87%.
This is not a hypergrowth biotech rocket. This is a steady industrial pharma engine.
Now let’s decode what exactly they manufacture — and why America matters so much.
3. Business Model – WTF Do They Even Do?
Imagine this.
The US healthcare system is expensive. Branded drugs are costly. When patents expire, generic manufacturers jump in like bargain hunters on Flipkart sale day.
That’s where Aurobindo shines.
Formulations (87% of revenue)
They manufacture:
- Oral solids
- Liquids
- Injectables
- Specialty & oncology products
- OTC
US formulations mix (Q3 FY25):
Gx Orals – 68%
Specialty & Injectables – 18%
Branded Oncology – 8%
OTC – 6%
USA contributes 53% of total revenue.
That means if US FDA sneezes… Aurobindo catches a regulatory cold.
API Business (13%)
APIs are active ingredients used in medicines. They produce 19,000 MTPA capacity.
Beta-lactam accounts for 72% of API revenue now — up from 64% earlier. That means focus is shifting.
And in FY24, they commercialized Penicillin-G manufacturing (15,000 TPA) under PLI scheme.
Translation: They want vertical integration power.
So here’s the real question — are they a generics company slowly transforming into a specialty + biosimilar powerhouse?
Let’s
